News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
SCHMIDT ERIC THOMAS
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 06/12/2023 |
4
| SCHMIDT ERIC THOMAS (Director) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Granted 5,200 shares
@ $0
Granted 18,400 options to buy
@ $24.84, valued at
$457.1k
|
|
| 05/30/2023 |
4
| SCHMIDT ERIC THOMAS (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 92,958 options to buy
@ $3.37, valued at
$313.3k
|
|
| 03/24/2023 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 558,094 shares
@ $0
Granted 432,738 options to buy
@ $5.04, valued at
$2.2M
|
|
| 03/16/2023 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Paid exercise price by delivering 35,879 shares
@ $5.47, valued at
$196.3k
|
|
| 12/20/2022 |
4
| SCHMIDT ERIC THOMAS (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Granted 57,042 options to buy
@ $3.37, valued at
$192.2k
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/25/2022 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 237,358 shares
@ $0
Granted 368,589 options to buy
@ $9.69, valued at
$3.6M
|
|
| 03/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/21/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 06/24/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/26/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/30/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/17/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/19/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/11/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 11/18/2020 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 4,634 shares
@ $32.6, valued at
$151.1k
Sold 10,366 shares
@ $33, valued at
$342.1k
|
|
| 10/16/2020 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 5,104 shares
@ $39.4674, valued at
$201.4k
Sold 4,218 shares
@ $40.0689, valued at
$169k
Sold 3,479 shares
@ $41.3336, valued at
$143.8k
Sold 2,099 shares
@ $42.3247, valued at
$88.8k
Sold 100 shares
@ $43.01, valued at
$4.3k
|
|
| 09/22/2020 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 9,889 shares
@ $34.755, valued at
$343.7k
Sold 3,200 shares
@ $35.9591, valued at
$115.1k
Sold 1,911 shares
@ $37.04, valued at
$70.8k
|
|
| 06/19/2020 |
4
| SCHMIDT ERIC THOMAS (Director) has filed a Form 4 on Revolution Medicines, Inc.|
Txns:
| Granted 7,234 shares
@ $0
Granted 25,318 options to buy
@ $36.57, valued at
$925.9k
|
|
| 04/09/2020 |
4
| SCHMIDT ERIC THOMAS (Director) has filed a Form 4 on RELMADA THERAPEUTICS, INC.|
Txns:
| Exercised (in-or-at-the-money) 32,500 options to buy
@ $6, valued at
$195k
Exercised (in-or-at-the-money) 12,500 options to buy
@ $9, valued at
$112.5k
|
|
| 03/20/2020 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 30,800 shares
@ $0
Granted 109,600 options to buy
@ $18.22, valued at
$2M
|
|
| 03/18/2020 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Sold 5,150 shares
@ $19.6957, valued at
$101.4k
Sold 300 shares
@ $20.25, valued at
$6.1k
|
|
| 02/24/2020 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Disposed of 237,155 shares
@ $25.3, valued at
$6M
|
|
| 03/15/2019 |
4
| SCHMIDT ERIC THOMAS (CFO) has filed a Form 4 on Allogene Therapeutics, Inc.|
Txns:
| Granted 49,400 shares
@ $0
Granted 83,500 options to buy
@ $26.89, valued at
$2.2M
|
|
|
|